UT MD Anderson announces historic expansion of cancer care facilities
The University of Texas MD Anderson Cancer Center today announced the historic expansion of its Texas Medical Center (TMC) campus through two new facilities: Inspiration Tower and Prism. Together, these facilities will fundamentally reshape the future of cancer care and elevate patient experience, enabling UT MD Anderson to care for nearly 250,000 patients annually.
Inspiration Tower and Prism will serve as the new front door to UT MD...
Susan Bullman receives TAMEST Mary Beth Maddox Award for breakthrough tumor microbiome research
Susan Bullman, Ph.D., associate professor of Immunology and Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer...
Allison Institute convenes leading scientists and clinicians for fourth annual scientific symposium on frontiers of immunotherapy
Annual meeting focused on immune set points andthe regulatory mechanisms shaping the next generation of cancer immunotherapies
Symposium featured...
Newly discovered pathway fuels production of cancer-driving proteins
Researchers identified a previously unknown mechanism that helps cancer cells produce cancer-promoting proteins, including KRAS
Blocking a specific enzyme reduced tumor growth in preclinical models of common cancer types
Loss of the enzyme also improved response to KRAS-targeted drugs and counteracted treatment resistance
The findings suggest this enzyme could be a target for KRAS-driven cancers
A previously unknown mechanism helps...
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
Phase 3 trial finds that next-generation KRAS G12C inhibitor divarasib significantly reduced risk of cancer progressing and death...
ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer
ABSTRACTS: 3438O, 4244RO, 540RO, 2490P
Researchers at The University of Texas MD Anderson Cancer Center presented new findings at the...
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
Patients receiving durvalumab plus olaparib lived almost one year longer than patients treated with chemotherapy alone
Study...
UT MD Anderson welcomes eight new members to Board of Visitors
The University of Texas MD Anderson Cancer Center is pleased to announce eight new members to its Board of Visitors (BOV), the institution...
UT MD Anderson names 2026 winners of The Brown Foundation Award for Excellence in Oncology Nursing
The University of Texas MD Anderson Cancer Center yesterday awarded Lakeisha Keller-Davis, RN, MSN, CMSRN, and Ellen C. Mullen, Ph.D., APRN-BC...
UT MD Anderson’s Albert Koong and Katy Rezvani elected to the National Academy of Medicine
Albert Koong, M.D, Ph.D., honored for advances in radiation therapy technologies and new discoveries in cancer biology
Katy Rezvani...